Agency
Planned Parenthood Pasadena and San Gabriel Valley INC
Planned Parenthood Pasadena and San Gabriel Valley INC was paid $15.73M by Medicaid between Jan 2018 and Dec 2024, across 63 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 16% of everything it billed.
33Billing provider infoPLANNED PARENTHOOD PASADENA AND SAN GABRIEL VALLEY INC
PASADENA, CA 91104
PASADENA, CA 91104
33aNPI1073669040assigned 01/25/2007
33bProvider typeVoluntary or Charitable Agency
28Total paid$15.73M
24GClaims584,439
24DCodes billed63
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Voluntary or Charitable Agency providers in California
Rank by total paid#1 of 35
Median peer was paid$847K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 95,267 | $2.94M | |
| 2019 | 68,957 | $1.71M | |
| 2020 | 67,765 | $2.13M | |
| 2021 | 78,012 | $2.29M | |
| 2022 | 69,653 | $1.77M | |
| 2023 | 114,950 | $2.96M | |
| 2024incomplete | 89,835 | $1.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 35,512 | 34,748 | $2.54M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 15% | 91,662 | 87,686 | $2.40M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 14% | 91,526 | 87,718 | $2.18M |
| J3490 | Unclassified drugs | 7.8% | 51,482 | 44,952 | $1.23M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.6% | 10,054 | 9,939 | $1.03M |
| S4993 | Contraceptive pills for birth control | 5.5% | 7,955 | 7,838 | $858K |
| 87806 | 5.2% | 43,654 | 38,771 | $810K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.8% | 13,027 | 12,772 | $762K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 4.0% | 31,320 | 31,242 | $635K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.0% | 3,178 | 3,158 | $631K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.7% | 15,555 | 15,389 | $578K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.2% | 4,353 | 4,330 | $501K |
51 more codes
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 1.4% | 385 | $223K |
| 81025 | 1.2% | 45,656 | $183K | |
| A4267 | Contraceptive supply, condom, male, each | <1% | 32,066 | $135K |
| Q3014 | Telehealth originating site facility fee | <1% | 7,805 | $132K |
| 99201 | <1% | 1,326 | $120K | |
| 99000 | <1% | 31,774 | $113K | |
| S5199 | Personal care item, nos, each | <1% | 12,160 | $82K |
| S0199 | Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs | <1% | 228 | $81K |
| 59840 | <1% | 643 | $70K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 295 | $66K |
| 11981 | <1% | 388 | $64K | |
| S5000 | Prescription drug, generic | <1% | 6,676 | $37K |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 2,638 | $34K |
| 83986 | <1% | 14,190 | $33K | |
| 58300 | <1% | 518 | $33K | |
| 87210 | <1% | 9,392 | $25K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 411 | $20K |
| 11976 | <1% | 426 | $17K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 3,128 | $17K |
| S5001 | Prescription drug, brand name | <1% | 4,695 | $14K |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 25 | $12K |
| 90651 | <1% | 53 | $11K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 16 | $9K |
| 81002 | <1% | 3,679 | $6K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 910 | $6K |
| 85018 | <1% | 733 | $4K | |
| S0190 | Mifepristone, oral, 200 mg | <1% | 84 | $3K |
| 82120 | <1% | 1,219 | $3K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,889 | $3K |
| 57454 | <1% | 48 | $3K | |
| J7303 | Contraceptive supply, hormone containing vaginal ring, each | <1% | 12 | $2K |
| 58301 | <1% | 81 | $2K | |
| 99152 | <1% | 75 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 70 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 67 | $850.09 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 232 | $843.82 |
| 11982 | <1% | 23 | $723.91 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $654.92 |
| 0012A | <1% | 15 | $600.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 124 | $519.74 |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 220 | $470.51 |
| 36415 | Collection of venous blood by venipuncture | <1% | 519 | $392.75 |
| 90756 | <1% | 21 | $298.48 | |
| 86901 | <1% | 103 | $290.24 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 12 | $178.08 |
| 96127 | <1% | 36 | $152.97 | |
| 99406 | <1% | 14 | $96.73 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12 | $50.32 |
| 86592 | <1% | 14 | $21.40 | |
| A4268 | Contraceptive supply, condom, female, each | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBONNER, SHERI (PRESIDENT CEO)